Billionaire Ken Griffin Is Selling Palantir and Buying a Stock Wall Street Expects to Rocket 139% Higher

Billionaire Ken Griffin Is Selling Palantir and Buying a Stock Wall Street Expects to Rocket 139% Higher

The Securities and Exchange Commission requires wealthy stock traders to disclose their transactions every three months. Citadel sold Palantir shares but invested in Summit Therapeutics, a clinical-stage cancer drug developer with promising results, indicating potential growth.

Read More

Did you find this insightful?